<DOC>
	<DOCNO>NCT01578707</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment ibrutinib monotherapy result clinically significant improvement progression free survival ( PFS ) compare treatment ofatumumab patient relapse refractory Chronic Lymphocytic Leukemia ( CLL ) Small Lymphocytic Lymphoma ( SLL )</brief_summary>
	<brief_title>A Phase 3 Study Ibrutinib ( PCI-32765 ) Versus Ofatumumab Patients With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Study PCYC-1112-CA randomize , multicenter , open-label , phase 3 study Bruton 's Tyrosine Kinase ( BTK ) inhibitor Ibrutinib ( PCI-32765 ) versus Ofatumumab patient Relapsed Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma . Patients randomize ofatumumab arm may consider receive next subsequent therapy ibrutinib .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>ECOG performance status 01 . Diagnosis CLL SLL meet IWCLL 2008 criterion . Active disease meeting least 1 IWCLL 2008 criterion require treatment . Must receive least one prior therapy CLL/SLL . Considered appropriate treatment retreatment purine analog base therapy . Measurable nodal disease CT . Patients must able receive outpatient treatment laboratory monitor institution administers study drug entire study . Known CNS lymphoma leukemia . No documentation cytogenetic and/or FISH patient record prior first dose study drug . Any history Richter 's transformation prolymphocytic leukemia . Uncontrolled Autoimmune Hemolytic Anemia ( AIHA ) idiopathic thrombocytopenia purpura ( ITP ) . Prior exposure ofatumumab ibrutinib . Prior autologous transplant within 6 month prior first dose study drug . Prior allogeneic stem cell transplant within 6 month evidence active graft versus host disease requirement immunosuppressant within 28 day prior first dose study drug . History prior malignancy , exception certain skin cancer malignancy treat curative intent evidence active disease 3 year . Serologic status reflect active hepatitis B C infection . Unable swallow capsule disease significantly affect gastrointestinal function . Uncontrolled active systemic fungal , bacterial , viral , infection . History stroke intracranial hemorrhage within 6 month prior first dose study drug . Requires anticoagulation warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chronic</keyword>
	<keyword>SLL</keyword>
	<keyword>CLL</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>ibrutinib</keyword>
	<keyword>RESONATE</keyword>
	<keyword>Phase III</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
</DOC>